Cargando…

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

Drug resistance to sorafenib is common in patients with hepatocellular carcinoma(HCC). We examined the effects of a combination of sorafenib and fluvastatin on HCC using in vitro and in vivo models. The dual treatment induced apoptosis and reduced cellular viability in HCC more effectively than eith...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yang, Luo, RongCheng, Zheng, Hang, Wang, Biao, Liu, YaHui, Liu, DingLi, Chen, JinZhang, Xu, WanFu, Li, AiMin, Zhu, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410302/ https://www.ncbi.nlm.nih.gov/pubmed/28423574 http://dx.doi.org/10.18632/oncotarget.15575

Ejemplares similares

Protein kinase D2 contributes to TNF-α-induced epithelial mesenchymal transition and invasion via the PI3K/GSK-3β/β-catenin pathway in hepatocellular carcinoma
por: Zhu, Yun, et al.
Publicado: (2015)

Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma
por: Mercurio, Sandy, et al.
Publicado: (2013)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin
por: Li, Jun, et al.
Publicado: (2018)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells
por: TOMIZAWA, MINORU, et al.
Publicado: (2014)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

Modulation of Ion Channels in the Superior Cervical Ganglion Neurons by Myocardial Ischemia and Fluvastatin Treatment
por: Cheng, Lijun, et al.
Publicado: (2018)

Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation
por: Wang, Xiaoli, et al.
Publicado: (2020)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
por: Zhang, Yafei, et al.
Publicado: (2012)

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
por: Lee, Chong-Ki, et al.
Publicado: (2013)

Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy
por: Yang, Zuozhang, et al.
Publicado: (2017)

miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2021)

NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma
por: Wang, Chonggao, et al.
Publicado: (2022)

Effects of Fluvastatin on Characteristics of Stellate Ganglion Neurons in a Rabbit Model of Myocardial Ischemia
por: Cheng, Li-Jun, et al.
Publicado: (2016)

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib
por: Duan, Wendu, et al.
Publicado: (2018)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

Kinetic Spectrophotometric Determination of Fluvastatin in Pharmaceutical Preparations
por: Ashour, Safwan, et al.
Publicado: (2010)

Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells
por: Cai, Hongqiao, et al.
Publicado: (2019)

Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells
por: Youssef , Mohieldin M., et al.
Publicado: (2016)

Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines
por: Chung, Yong-Gyu, et al.
Publicado: (2018)

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
por: Liu, Jianhua, et al.
Publicado: (2017)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
por: Seyhoun, Iman, et al.
Publicado: (2019)

Fluvastatin Sodium Ameliorates Obesity through Brown Fat Activation
por: Yin, Na, et al.
Publicado: (2019)

Sorafenib-Loaded Cu(2−x)Se Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma
por: Huang, An-Tian, et al.
Publicado: (2022)

Inhibition of Candida albicans by Fluvastatin Is Dependent on pH
por: Schmidt, Martin, et al.
Publicado: (2009)

Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers
por: El-Helw, Abdel-Rahim M, et al.
Publicado: (2015)

Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis
por: Jin, Mengdi, et al.
Publicado: (2021)

Fluvastatin use and risk of acute pancreatitis: a population-based case-control study in Taiwan
por: Liao, Kuan-Fu, et al.
Publicado: (2017)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
por: Bort, Alicia, et al.
Publicado: (2017)

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells
por: Lin, Chi-Kang, et al.
Publicado: (2019)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

The Association Between Body Mass Index and the Prognosis and Postoperative Complications of Hepatocellular Carcinoma: A Meta-Analysis
por: Rong, Xiaoxiang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i5g7efnok7i7g53mqm711mq4pb